Genmab A/S (GMAB) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the GenMAP full year 2025 financial results conference call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans, or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. GenMAP is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results, unless this is required by law. Please also note, GERMAP may hold your personal data as indicated by you as a part of our investor relations outreach activities in order to update you on GERMAP going forward. Please refer to our website for more information on GERMAP and our privacy policy. I would now like to hand the conference over to our first speaker today, Jan van der Winkel. Please go ahead. Hello and welcome to our financial results call for 2025. With me today is our Chief Financial Officer, Anthony Pagano, and our Chief Commercial Officer, Brad Bailey. For the Q&A, we will be joined by our Chief Medical Officer, Tanya Mahdi, and our Chief Development Officer, Judith Klimovski. As noted, we will be making forward-looking statements, so please keep that in mind. As we reflect on 2025, I would like to remind you of the commitments that we made at the beginning of the year. We said that we would accelerate the development of our high impact late-stage pipeline, that we would maximize the potential of our commercialized medicines, and that we would deliver on our capital allocation priorities. I'm pleased to say that we have delivered on these commitments. And we begin 2026 with a diversified, high-quality revenue base and a late...